A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 ``PembroRad'' trial.

Xu Shan Sun , Christian Sire , Yungan Tao , Laurent Martin , Marc Alfonsi , Jean Briac Prevost , Michel Rives , Cedrik Lafond , Jean-Marc Tourani , Julian Biau , Lionnel Geoffrois , Alexandre Coutte (1) , Xavier Liem , Elodie Vauleon , Franck Drouet , Jean-Francois Ramee , Gabriel Waksi , Laura Sinigaglia , Anne Auperin , Jean Bourhis

1 CHIMERE - CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516

Domaines: Sciences du Vivant [q-bio]

Xu Shan Sun, Christian Sire, Yungan Tao, Laurent Martin, Marc Alfonsi, et al.. A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 ``PembroRad'' trial.. Journal of Clinical Oncology, 2018, 36 (15, S), ⟨10.1200/JCO.2018.36.15\_suppl.6018⟩. ⟨hal-03600480⟩